Global WholeHealth Partners Corp. (OTC: GWHP), is Approved to Sell Through Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021; Global's Newly Designed Tests Are Now Ready for the Launch into the Retail Marketplace

Rhea-AI Summary

Global WholeHealth Partners Corp. (OTC: GWHP) announced it is now funded for growth through an agreement with EMC2 Funding, allowing for the purchase of up to $100 million in stock over 36 months. The company plans to launch five over-the-counter products, including pregnancy and drug tests, in retail. With partnerships established with major platforms like Walmart and Amazon, Global aims to leverage their extensive traffic and user base to drive sales. The company currently has 70 FDA-approved products, focusing on in-vitro diagnostics.

Positive

• Funding secured for growth through EMC2 agreement for up to $100 million.
• Plans to market five OTC products, enhancing product portfolio.
• Strategic partnerships with Walmart and Amazon expand distribution channels.

Negative

• Market acceptance of new products is uncertain.
• Potential risks include competition from larger companies and regulatory challenges.

Global WholeHealth Partners Corp. (OTC: GWHP) is Now Funded for Growth, Sales, and Expansion from EMC2 Funding.

Global is Presenting 5 OTC (Over the Counter) Products to be Sold in the Retail Marketplace.

SAN CLEMENTE, CA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global is planning on selling the Pregnancy, Ovulation, Drug Tests, Glucose, and Colorectal Cancer Tests to start the retail marketing. Global knows that it only gets one chance to show well, so it has spent several weeks with graphic artists and marketing designers to make sure, Global’s first impression is amazing.

In September 2020, Walmart.com had 385.5 million visits, up from 294.5 million visits in February 2020. This jump in website traffic is due to the global coronavirus epidemic, which has caused millions of people to stay at home and not visit stores in order to avoid infection.

Web visitor traffic to Walmart.com 2020 | Statista

Walmart will invest about $14 billion in 2021 on things like supply chain and automation, up from the $10.3 billion it spent on capital expenditures in the year that just ended.

Walmart Inc.’s online sales grew 79% for its fiscal year 2021, which ended Jan. 29. Its online sales also grew 69% in its Q4, the retail giant reported.

Walmart's online sales grow 79% in its just-ended fiscal year (digitalcommerce360.com)

With 300 million active users, the Amazon Seller Marketplace provides Global Wholehealth Partners Corporation a potentially massive audience of buyers and substantial visibility for its line of over-the-counter tests, including pregnancy, ovulation, drug, colorectal cancer, and glucose. 

Amazon receives more than 213 million unique US visitors every month according to a recent article by Tech Jury.

47 Amazon Statistics Everyone Must Know In 2021 | Techjury

“These latest deals (with Walmart online and Amazon Sellers Marketplace, eBay and Shopify) could easily become one of our largest points of distribution,” said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC: GWHP).

Global WholeHealth Partners Corp. (OTC: GWHP) through the EMC2 agreement is funded for growth, sales, and expansion. Per the terms of the EMC2 Purchase Agreement, we may direct EMC2 to purchase up to $100,000,000 worth of shares of our common stock under our agreement over a 36-month period, generally in amounts up to 100,000 shares of our common stock, which may be increased to up to 2,000,000 shares of our common stock depending on the market price of our common stock at the time of sale and subject to a maximum commitment by EMC2 of $500,000 per regular purchase per day. The total amount of shares to be sold through the EMC2 agreement is up to 8,578,177 shares of common stock. 

Global WholeHealth Partners Corp. (OTC:GWHP) provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

Global Wholehealth Partners Corp. (OTC:GWHP) provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Currently, the Company has 70 products FDA approved and many are approved for 10 OTC use, and 29 POC products approved by the FDA CLIA WAIVED.

Call or email about special prices for this announcement on all the tests.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Media Contact:
Name: Charles Strongo
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com 
Phone for Sales: 877-568-4947
www.gwhpcorp.com

Forward-Looking Statements

This press release contains "forward-looking statements.”  Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

FAQ

What is GWHP's new funding strategy?

Global WholeHealth Partners Corp. secured funding for growth through a $100 million agreement with EMC2.

What products is GWHP launching?

GWHP plans to launch five OTC products, including pregnancy and drug tests.

How will GWHP benefit from partnerships with Walmart and Amazon?

These partnerships provide significant exposure and access to large customer bases, increasing potential sales.

What financial risks does GWHP face?

GWHP faces risks such as market acceptance of products and intense competition from larger companies in the medical device sector.

How many FDA-approved products does GWHP have?

GWHP currently has 70 FDA-approved products, including various in-vitro diagnostic tests.